What Drives Pharmaceutical R&D Success? New Benchmarking Reveals Why Some Drug Pipelines Outperform Others

Pharmaceutical R&D success rates remain one of the industry's most closely watched performance indicators. Every investigational medicine represents years of scientific research, billions of dollars in investment, and significant commercial risk. Yet only a small proportion of programmes ultimately reach regulatory approval.

Understanding why some companies consistently achieve higher success rates than others has therefore become a strategic priority for pharmaceutical leaders. A new Drug Discovery Today analysis provides one of the most comprehensive industry benchmarks published to date.

Image

Measuring Success in Pharmaceutical R&D

Drug discovery is often described as a numbers game. Thousands of compounds may be screened before a handful progress into preclinical development, and only a fraction of clinical candidates ultimately become approved medicines.

One of the most widely used measures of research productivity is the Likelihood of Approval (LoA), which estimates the proportion of investigational medicines entering clinical development that eventually receive regulatory approval.

Previous industry analyses have estimated overall clinical success rates of less than 10%, although these figures vary by therapeutic area, modality, disease biology, and sponsor.

The new benchmarking study demonstrates that success rates among leading pharmaceutical companies differ considerably, suggesting that organisational strategy plays a greater role than many assume.

Examining clinical development activity across 18 leading pharmaceutical companies, the researchers analysed 2,092 investigational drugs, almost 20,000 clinical trials, and every US FDA approval between 2006 and 2022 to identify the characteristics associated with stronger research productivity.

Rather than concluding that success depends on a single factor, the study argues that sustainable R&D performance reflects a combination of portfolio strategy, scientific quality, organisational discipline, and operational execution.

A Unique Benchmark Across the Pharmaceutical Industry

Unlike many previous studies that evaluate individual clinical trials, this research focused on company-level performance.

The investigators examined:

• 18 leading pharmaceutical companies
• 2,092 investigational drug programmes
• 19,927 clinical trials
• FDA approvals over a 17-year period
• Clinical development activity from 2006 to 2022

Image

The analysis linked every investigational asset with its associated clinical development programme before comparing FDA approvals across sponsors.

This allowed researchers to calculate company-specific likelihoods of approval while also examining broader indicators of R&D efficiency.

The resulting dataset represents one of the largest comparative analyses of pharmaceutical R&D productivity currently available.

Read Reimagine AI-driven Drug Discovery with Pharma Superintelligence

Reimagine AI-driven Drug Discovery with Pharma Superintelligence

Explore how AI-driven drug discovery is evolving through Pharmaceutical Superintelligence and what your organisation can do to keep up.

Success Rates Vary Far More than Expected

One of the study's most striking findings is the variation in R&D performance across companies.

Across all organisations analysed, the average likelihood of approval reached 14.3%, higher than many historic cross-industry estimates because the study focuses on established pharmaceutical companies with mature development capabilities.

However, individual company performance ranged from below 10% to above 22%.

Among the highest-performing organisations were:

At the opposite end of the spectrum, several companies achieved approval rates below 10%, despite substantial investment and extensive clinical portfolios.

The findings reinforce an important point.

Large R&D budgets alone do not guarantee higher productivity.

Image

Bigger Portfolios Do Not Automatically Create Better Outcomes

The pharmaceutical industry has traditionally assumed that expanding discovery portfolios increases the probability of commercial success.

The benchmarking study challenges this assumption.

Companies managing the largest numbers of investigational programmes did not consistently achieve the highest approval rates.

Similarly, sponsors conducting the greatest numbers of clinical trials were not necessarily the most productive.

For example, several companies managed more than 2,000 individual clinical studies during the evaluation period while producing approval rates close to or below the industry average.

Meanwhile, some organisations with considerably smaller portfolios generated substantially higher success rates.

This suggests that portfolio quality may matter more than portfolio size.

Increasingly, pharmaceutical companies appear to be prioritising more selective pipeline decisions rather than pursuing ever-larger numbers of development programmes.

Read First Quarter 2026 State of Digital Health Funding

First Quarter 2026 State of Digital Health Funding

Digital health funding hit $7.4B in Q1 2026, the highest since Q2 2022. The CB Insights State of Digital Health report reveals where capital is concentrating and why it matters for pharma leaders.

Image

What Distinguishes Higher-Performing Organisations?

The paper does not argue that one operational model explains superior R&D productivity. Instead, it identifies several recurring characteristics shared by companies with stronger approval rates.

Scientific focus

High-performing organisations often demonstrate clear therapeutic priorities rather than maintaining highly fragmented research portfolios.

Concentrating scientific expertise around selected disease areas enables deeper biological understanding, stronger translational research, and more informed development decisions.

Earlier portfolio discipline

Successful companies appear more willing to terminate weak programmes before expensive late-stage development.

Early portfolio pruning allows capital and scientific resources to be redirected towards candidates with stronger evidence.

Strong translational science

Improved target validation, biomarker strategies, and human disease biology continue to reduce attrition throughout clinical development.

As translational medicine improves, fewer compounds progress into costly Phase III studies without sufficient biological confidence.

Operational excellence

Efficient clinical execution also contributes to success.

Companies with mature development organisations often benefit from stronger trial design, more consistent operational processes, and greater regulatory experience.

Collectively, these factors reinforce that R&D productivity depends on organisational capability as much as scientific discovery.

Clinical Phase Balance Offers Another Important Sign

One particularly interesting metric examined by the researchers is the ratio between Phase I and Phase III clinical activity.

This ratio provides insight into portfolio strategy.

Some organisations maintain very broad early-stage pipelines, while others progress a greater proportion of programmes into later development.

Neither approach guarantees success.

Instead, the analysis suggests that companies achieving stronger approval rates generally maintain healthier progression through the development pathway rather than allowing large numbers of early projects to accumulate without sufficient evidence for advancement.

Portfolio balance therefore becomes an indicator of strategic discipline rather than simply research volume.

Scientific Quality Increasingly Outweighs Scale

Perhaps the study's most important message is that pharmaceutical R&D is gradually shifting away from a traditional “more is better” philosophy.

Modern drug discovery increasingly relies on:

• human genetics
• precision medicine
• biomarker-driven development
• AI-assisted target identification
• improved translational biology
• earlier evidence generation

These advances enable companies to make higher-quality investment decisions throughout development rather than relying on large numbers of programmes to compensate for uncertainty.

As a result, future R&D success may depend less on expanding discovery pipelines and more on improving decision quality at every stage of development.

Read Phenotypic Drug Discovery: Beyond the Target

Phenotypic Drug Discovery: Beyond the Target

Phenotypic drug discovery is reshaping how pharma finds first-in-class drugs. This analysis covers the methods, AI integration, and strategic decisions R&D leaders face in 2026.

Can AI and Precision Medicine Improve R&D Success Rates?

While the benchmarking study focuses on historical performance between 2006 and 2022, its findings have important effects on the future of pharmaceutical R&D.

Today’s discovery environment differs markedly from the one that produced much of the dataset analysed.

Artificial intelligence, human genetics, multi-omics, digital pathology, and real-world evidence are changing how companies identify drug targets and select candidates for development.

Image

Rather than increasing the number of molecules entering the clinic, many organisations are investing in technologies that improve decision quality earlier in the discovery process.

Examples include:

• AI-assisted target identification and validation
• Human genetic evidence to prioritise disease mechanisms
• Biomarker-driven patient stratification
• In silico toxicity prediction
• Digital pathology and imaging biomarkers
• Better translational disease models

The objective is not necessarily to discover more compounds. It is to discover better compounds with a higher probability of clinical success.

Several recent industry analyses have shown that programmes supported by strong human genetic evidence are significantly more likely to achieve regulatory approval than targets selected without comparable biological validation.

Likewise, AI is increasingly being used to reduce attrition by identifying safety liabilities, improving lead optimisation, and supporting clinical trial design before patients are enrolled.

Therefore, improving R&D productivity increasingly depends on improving scientific confidence before entering expensive clinical development.

The Era of the Blockbuster Pipeline Is Changing

Historically, pharmaceutical companies often pursued broad discovery portfolios in the hope that a small number of blockbuster medicines would offset numerous failures.

That strategy is becoming more difficult to sustain.

Today's pipelines increasingly include:

• precision medicines
• rare disease therapies
• cell and gene therapies
• RNA therapeutics
• antibody-drug conjugates (ADCs)
• radiopharmaceuticals
• highly targeted oncology medicines

These programmes typically involve smaller patient populations, more complex manufacturing, biomarker-driven clinical trials, and specialised regulatory pathways.

As a result, future R&D success is likely to depend less on portfolio volume and more on selecting programmes with the strongest biological rationale and greatest clinical differentiation.

The benchmarking analysis supports this shift. Organisations demonstrating disciplined portfolio management and higher-quality progression through development generally achieved stronger approval outcomes than those relying primarily on pipeline size.

Read Why Precision Alone Isn't Enough in Oncology Drug Discovery

Why Precision Alone Isn't Enough in Oncology Drug Discovery

Precision alone isn’t enough in oncology drug discovery. See why execution, biomarkers, and trial design determine scalable success in precision medicine.

Image

Lessons About Pharmaceutical R&D Success

The study offers several strategic lessons for those responsible for research investment and portfolio management.

Focus on portfolio quality

Large pipelines do not automatically produce better commercial outcomes. Organisations should continually evaluate whether each programme remains scientifically and commercially justified.

Invest earlier in translational science

Better target validation, biomarkers, and disease biology can prevent costly late-stage failures and improve capital allocation.

Treat attrition as a strategic metric

Failure is an inevitable part of drug discovery. However, terminating weaker programmes earlier allows resources to be redirected towards higher-value assets.

Strengthen organisational capability

The variation observed between companies suggests that operational excellence, scientific leadership, and development experience remain important competitive advantages alongside technological innovation.

Use AI to support better decisions

Artificial intelligence should augment scientific judgement rather than replace it. Used appropriately, AI can help prioritise targets, identify risks, synthesise evidence, and improve portfolio decision-making throughout the R&D lifecycle.

Measuring R&D Success Beyond Approval Rates

Likelihood of Approval remains one of the most useful measures of R&D productivity, but it should not be viewed in isolation.

Future assessments of pharmaceutical performance will increasingly incorporate additional measures, including:

Taken together, these indicators provide a more comprehensive picture of how effectively organisations convert scientific discovery into approved therapies.

Image

A More Disciplined Model of Pharma Innovation

The benchmarking study challenges one of the pharmaceutical industry's longest-standing assumptions: That larger pipelines inevitably produce greater innovation.

Instead, the evidence suggests that sustained R&D success depends on a combination of scientific excellence, portfolio discipline, operational execution, and strategic decision-making.

Companies that consistently outperform their peers appear to allocate capital more selectively, prioritise programmes with stronger biological evidence, and maintain greater discipline as candidates progress through development.

As technologies such as artificial intelligence, advanced genomics, and precision medicine continue to mature, the industry’s competitive advantage is likely to shift further towards organisations that make better decisions rather than simply more decisions.

Improving R&D productivity is therefore no longer just a question of increasing investment. It is about improving the quality of every decision made from target identification through to regulatory approval.

At Pharmatica, we analyse the strategies, technologies, and scientific advances shaping the future of therapeutic drug discovery. By translating complex research into practical Insights, we help pharmaceutical leaders understand how improvements in discovery science, portfolio management, and clinical development can deliver measurable gains in R&D productivity.

Pharmatica: Insight. Connection. Impact.